SCHEMBL4665837

SCHEMBL4665837

O=S(=O)(Nc1ccc(Nc2cc(-c3cccc4ccccc34)ncn2)cc1)c1ccccc1C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 14/20 0.50
CYP2C9 P11712 2/20 0.47
SLC22A6 Q4U2R8 2/20 0.47
SLC22A8 Q8TCC7 2/20 0.47
SLC22A11 Q9NSA0 2/20 0.47
PTPN2 P17706 3/20 0.47
PTPN1 P18031 3/20 0.47
PTPN5 P54829 3/20 0.47
SLC40A1 Q9NP59 1/20 0.45
CYP3A4 P08684 2/20 0.45
CYP1A2 P05177 1/20 0.45
HSPD1 P10809 1/20 0.44
HSPE1 P61604 1/20 0.44
RORA P35398 1/20 0.43
RORC P51449 1/20 0.43
NR1H2 P55055 1/20 0.43
NR1H4 Q96RI1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4663833 0.87 CYP1A2 (0.47) CYP2C9PTPN2PTPN1PTPN5CYP3A4
SCHEMBL4665802 0.82 CYP1A2 (0.50) CYP2C9CYP3A4CYP1A2RORC
SCHEMBL4666155 0.82 CYP1A2 (0.48) CYP2C9SLC40A1CYP3A4CYP1A2
SCHEMBL4664312 0.79 SLC22A12 (0.52) SLC22A12CYP2C9CYP3A4CYP1A2
SCHEMBL4667473 0.79 MEN1 (0.51) CYP2C9CYP3A4CYP1A2
SCHEMBL4666195 0.78 TNNI3K (0.50) CYP2C9PTPN2PTPN1PTPN5CYP3A4
SCHEMBL4666141 0.78 TNNI3K (0.49) CYP2C9PTPN2PTPN1PTPN5CYP3A4
SCHEMBL4666159 0.77 KMO (0.48) CYP2C9PTPN2PTPN1PTPN5CYP3A4
SCHEMBL4665695 0.76 CYP1A2 (0.47) CYP2C9CYP3A4CYP1A2
SCHEMBL4665768 0.75 TNNI3K (0.46) CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 SLC22A12 4353/4885CYP2C9 1047/4885SLC22A6 3766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.